Management of post-chemotherapy residual masses in advanced seminoma

被引:62
作者
Fléchon, A [1 ]
Bompas, E [1 ]
Biron, P [1 ]
Droz, JP [1 ]
机构
[1] Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France
关键词
testes; seminoma; drug therapy; cisplatin; neoplasm; residual;
D O I
10.1016/S0022-5347(05)64275-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We studied the resection of post-chemotherapy residual masses (20% to 80%) of advanced seminoma complicated by extensive fibrosis, in which active disease appears in 10% to 20% of cases. Materials and Methods: We retrospectively analyzed (1986 to 2000) residual mass evolution according to size in 79 platinum treated patients. Results: There was an evaluable response in 78 patients, including toxic death in 1 after 1 chemotherapy cycle, a complete response in 34 (after chemotherapy in 15 and after complete residual mass resection in 19), a marker negative partial response in 42 (incomplete residual mass resection in 8), stable and progressive disease in 1 each. In 15 of 31 patients the resected residual mass was 3 cm. or greater, whereas in 12 of 29 it was less than 3 cm. No surgery was performed for 3 residual masses of unknown size. Of the 42 residual masses 21 disappeared at a median of 12.5 months. Progression occurred at the initial tumor site in 11 of 13 patients after a median of 3.5 months, including 3 with a complete response, 8 with a marker negative partial response (residual mass 3 cm. or greater in 3, less than 3 cm. in 4 and unknown size in 1) and treatment failure in 2 (residual mass 3 cm. or greater). At a median followup of 36.4 months 67 patients survived (no disease progression in 56 and nonevolving residual masses in 11), while 12 had died including 9 of progressive disease 1 of toxicity and 2 of other causes. Conclusions: In our study there was incomplete surgical resection in 30% of cases. Relapse in 16.6% of cases occurred rapidly after the end of chemotherapy. Viable cells were only noted in residual masses 3 cm. or greater (13%) and 50% of residual masses disappeared during surveillance. We intend. to perform a prospective cohort study with close followup of patients with residual masses less than 3 cm. using an indication for surgery tailored to positron emission tomography findings in those with residual masses 3 cm. or greater.
引用
收藏
页码:1975 / 1979
页数:5
相关论文
共 21 条
  • [1] [Anonymous], 1997, J Clin Oncol, V15, P594
  • [2] A RANDOMIZED TRIAL OF ETOPOSIDE + CISPLATIN VERSUS VINBLASTINE + BLEOMYCIN + CISPLATIN + CYCLOPHOSPHAMIDE + DACTINOMYCIN IN PATIENTS WITH GOOD-PROGNOSIS GERM-CELL TUMORS
    BOSL, GJ
    GELLER, NL
    BAJORIN, D
    LEITNER, SP
    YAGODA, A
    GOLBEY, RB
    SCHER, H
    VOGELZANG, NJ
    AUMAN, J
    CAREY, R
    FAIR, WR
    HERR, H
    MORSE, M
    SOGANI, P
    WHITMORE, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (08) : 1231 - 1238
  • [3] Culine S, 1998, EUR J CANCER, V34, P353
  • [4] Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma
    De Santis, M
    Bokemeyer, C
    Becherer, A
    Stoiber, F
    Oechsle, K
    Kletter, K
    Dohmen, BM
    Dittrich, C
    Pont, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (17) : 3740 - 3744
  • [5] Radiotherapy after chemotherapy for metastatic seminoma - A diminishing role
    Duchesne, GM
    Stenning, SP
    Aass, N
    Mead, GM
    Fossa, SD
    Oliver, RTD
    Horwich, A
    Read, G
    Roberts, IT
    Rustin, G
    Cullen, MH
    Kaye, SB
    Harland, SJ
    Cook, PA
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (06) : 829 - 835
  • [6] CHEMOTHERAPY OF ADVANCED SEMINOMA - CLINICAL-SIGNIFICANCE OF RADIOLOGICAL FINDINGS BEFORE AND AFTER TREATMENT
    FOSSA, SD
    KULLMANN, G
    LIEN, HH
    STENWIG, AE
    OUS, S
    [J]. BRITISH JOURNAL OF UROLOGY, 1989, 64 (05): : 530 - 534
  • [7] Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy
    Fossa, SD
    Oliver, RTD
    Stenning, SP
    Horwich, A
    Wilkinson, P
    Read, G
    Mead, GM
    Roberts, JT
    Rustin, G
    Cullen, MH
    Kaye, SB
    Harland, SJ
    Cook, P
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) : 1380 - 1387
  • [8] CISPLATIN, VINCRISTINE AND IFOSPHAMIDE COMBINATION CHEMOTHERAPY OF METASTATIC SEMINOMA - RESULTS OF EORTC TRIAL-30874
    FOSSA, SD
    DROZ, JP
    STOTER, G
    KAYE, SB
    VERMEYLEN, K
    SYLVESTER, R
    [J]. BRITISH JOURNAL OF CANCER, 1995, 71 (03) : 619 - 624
  • [9] THERAPEUTIC GUIDELINES AND RESULTS IN ADVANCED SEMINOMA
    FRIEDMAN, EL
    GARNICK, MB
    STOMPER, PC
    MAUCH, PM
    HARRINGTON, DP
    RICHIE, JP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (10) : 1325 - 1332
  • [10] Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma
    Ganjoo, KN
    Chan, RJ
    Sharma, M
    Einhorn, LH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3457 - 3460